Sanofi-Aventis bolsters inflammation pipeline with antibody deal
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has sublicensed from Kyowa Hakko Kirin (KHK) the global rights to a novel immunoregulating antibody with potential in gastrointestinal indications and rheumatoid arthritis.